New blood test could spot key mutations in Hard-to-Treat prostate cancer
NCT ID NCT06762379
First seen Apr 03, 2026 · Last updated May 14, 2026 · Updated 7 times
Summary
This study aims to improve how doctors detect HRR gene mutations in men with metastatic prostate cancer. Instead of relying on tumor tissue, which is often hard to get, researchers will use a simple blood test (liquid biopsy). The goal is to validate this new testing method so more patients can benefit from targeted treatments. About 125 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER (MPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
European Institute of oncology
RECRUITINGMilan, Italy, 20141, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.